'Gray Market' Retatrutide Study; Menopause and the Brain; Drug Allergy Warnings
(MedPage Today) -- People who took "gray market" compounded retatrutide, an investigational triple hormone receptor agonist, achieved less weight loss with up to 12 months of treatment than clinical trial participants, a preprint study suggested...
A preprint study revealed that people who used unauthorized compounded retatrutide, a hormone receptor agonist, saw reduced weight loss compared to those in clinical trials over a year-long period. In New York City, sanitation workers reported being pricked by improperly discarded injector pens containing GLP-1 medications. Strength training during pregnancy enhanced maternal well-being but did not lower gestational diabetes rates in a randomized controlled trial involving overweight women.
A 17-year-old diabetic patient passed away 24 days after being placed in a foster home that lacked a license to care for him. The U.S. Departments of Veterans Affairs and Defense revised their obesity management guidelines to promote personalized, adaptable approaches to medication use and discourage patients from discontinuing beneficial drugs to avoid weight regain.
Data from Epic Health Research Network indicated that outpatient women's hormone therapy usage nearly doubled between 2017 and 2026, driven primarily by progestin-only and estrogen-only preparations. Natural menopause, independent of aging, did not significantly impact thyroid function in a Japanese cohort analysis. Research indicated that an earlier onset of menopause was linked to quicker cognitive decline, a higher risk of Alzheimer's disease, and greater accumulation of white matter hyperintensities.
Novo Nordisk is currently testing lower doses of oral semaglutide for weight loss in its phase III OASIS 5 study, exploring options below the approved 25 mg maintenance dose. Vitruvias Therapeutics issued a recall of one lot of Thyroid Tablets, USP 30 mg, due to potential superpotency, as reported by the FDA. Additionally, parathyroid imaging should only be performed when a confirmed diagnosis of primary hyperparathyroidism is made to prevent unnecessary radiation exposure.
Lastly, new allergy warnings were added to four osteoporosis drugs and one hypoparathyroidism drug, according to a MedShadow report.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
